Bonanza of New Treatment Regimens for Multiple Myeloma: What Is Right for My Patient?

Presenter: Shaji K. Kumar
Restricted access

Although recent advances in the treatment of multiple myeloma have improved survival, it remains a chronic disease that requires a long-term treatment strategy. The key to achieving the best outcomes for patients is delivering the best “package” of treatment at a given stage. This means using optimal combinations that maximize benefit based on what patients have received previously and minimize treatment-related toxicity. Sequencing of regimens also plays an important role. As new agents and new classes of drugs continue to be approved for multiple myeloma, future strategies will use more individualized approaches to treatment.

Disclosures: Dr. Kumar has disclosed that he has received honoraria from BeiGene; grant/research support from AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics, Celgene Corporation, Janssen Pharmaceutica Products, LP, Kite Pharma, MedImmune Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Roche Laboratories, Inc., sanofi-aventis U.S., Takeda Pharmaceuticals North America, Inc., TeneBio; and consulting fees from Cellectar Biosciences, GeneCentrix, Inc, Oncopeptides. He is also a scientific advisor for AbbVie, Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Janssen Pharmaceutica Products, LP, MedImmune Inc., and sanofi-aventis U.S.

Correspondence: Shaji K. Kumar, MD, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905. Email: Kumar.shaji@mayo.edu
  • 1.

    Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet 2017;389:519527.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Kumar S, Jacobus SJ, Cohen AD, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial [published online June 01, 2020]. J Clin Oncol, doi: 10.1200/JCO.2020.38_suppl.LBA3

    • Search Google Scholar
    • Export Citation
  • 3.

    Kumar SK, Berdeja JG, Niesvizky R, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia 2019; 33:17361746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380:21042115.

  • 5.

    Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomized, open-label, phase 3 study. Lancet 2019;394:2938.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136:936945.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Costa L, Chhabra S, Godby K, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM) [abstract 653]. Presented at the 2019 American Society of Hematology Annual Meeting; December 7, 2019; Orlando, Florida.

    • Crossref
    • Export Citation
  • 8.

    Kapoor P, Gertz MA, Laplant B, et al. Phase 2 trial of daratumumab, ixazomib, lenalidomide and modified dose dexamethasone in patients with newly diagnosed multiple myeloma [abstract]. Blood 2019;134(Suppl 1):Abstract 864.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomized, open-label, phase 3 trial. Lancet 2020;395:132141.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:13271337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:20962107.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:18111822.

  • 13.

    Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130:974981.

  • 14.

    Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015;126:22842290.

  • 15.

    Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396:186197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA phase III study design. Future Oncol 2020;16:43474358.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Chari A, Vogl DT, Dimopoulos MA, et al. Results of the pivotal STORM study (part 2) in penta-refractory multiple myeloma (MM): deep and durable responses with oral selinexor plus low dose dexamethasone in patients with penta-refractory MM [abstract]. Blood 2018;132(Suppl 1):Abstract 598.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Dimopoulos MA, Delimpasi S, Simonova M, et al. Weekly selinexor, bortezomib and dexamethasone versus twice weekly bortezomib and dexamethasone in patients with multiple myeloma after 1-3 prior therapies: initial results of the phase III BOSTON study. Presented at the 2020 ASCO Virtual Scientific Program; May 29, 2020. Abstract 8501.

    • Crossref
    • Export Citation
  • 19.

    Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207221.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Nooka AK, Stockerl-Goldstein K, Quch H, et al. DREAMM-6: safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 8502.

    • Crossref
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 982 982 8
PDF Downloads 165 165 4
EPUB Downloads 0 0 0